Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
102 studies found for:    Open Studies | Interleukin
Show Display Options
Rank Status Study
1 Recruiting Interleukin-2—Induced Cognitive/Affective/Sleep Symptoms
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Melanoma;   High-dose Interleukin-2
Intervention:
2 Recruiting Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk
Condition: Abortion, Spontaneous
Intervention: Genetic: IL-10 polymorphism
3 Recruiting Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Interleukin-2
4 Not yet recruiting Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
Condition: Autoimmune Hemolytic Anemia
Intervention: Drug: Interleukine-2
5 Recruiting Interleukin-1 Blockade in HF With Preserved EF
Condition: Heart Failure With Normal Ejection Fraction
Interventions: Drug: Anakinra;   Drug: Placebo
6 Recruiting Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis
Condition: Hand Osteoarthritis
Interventions: Drug: tocilizumab;   Drug: saline solution
7 Recruiting MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine;   Procedure: TIL (T-cells);   Drug: IL-2;   Drug: MK-347;   Behavioral: Questionnaires;   Behavioral: Phone Calls
8 Recruiting Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
Condition: Acute Myocardial Infarction
Interventions: Drug: Anakinra 100 mg;   Drug: Placebo
9 Recruiting Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices
Condition: Heart Failure
Intervention: Drug: Anakinra
10 Not yet recruiting Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Drug: Pembrolizumab;   Drug: Interleukin-2
11 Recruiting Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Participants With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2)
12 Recruiting Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor-Infiltrating Lymphocytes;   Biological: Low-Dose Interleukin
13 Recruiting Study of Lymphodepletion Plus Adoptive Cell Transfer With T-Cells Transduced With CXCR2 and Nerve Growth Factor Receptor (NGFR) Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
14 Recruiting "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs);   Biological: Interleukin-2;   Drug: Cyclophosphamide
15 Recruiting Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: Ad5-yCD/mutTKSR39rep-hIL12
16 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
17 Not yet recruiting M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
18 Recruiting Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
Condition: Liver Transplantation
Intervention: Biological: Interleukin-2
19 Recruiting Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Genetic: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
20 Recruiting Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Condition: Renal Cell Carcinoma
Interventions: Biological: High Dose IL-2;   Radiation: SBRT

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.